GeneQuantum, MITRO partner up on radionuclide conjugates



Suzhou’s GeneQuantum Healthcare and the Nanjing-based MITRO Biotech formed a strategic cooperation agreement focused on the development of next generation radionuclide conjugates. According to the press release, GeneQuantum’s bioconjugation platform will be paired with MITRO’s radiolabeling and molecular imaging capabilities to jointly develop radionuclide conjugates that will enable companion diagnostics and targeted therapy for tumors. No financials were disclosed.

GeneQuantum was set up in 2013 based around its proprietary intelligent ligase-dependent conjugation (iLDC) platform, while MITRO was founded in 2010 as the first molecular imaging CRO in China. The partnership is GeneQuantum’s second in a matter of months, after the firm signed up with Beijing-headquartered Biocytogen for development of tumor immunotherapy bioconjugates in a November 2018 deal, as reported by GBI.
Reference:

Related news
China-based Sino Biopharmaceutical Limited (HKX.1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, received marketing approval from the National Medical Products Administration (NMPA) for a generic version of the oral cancer drug lenalidomide.
Germany-based giant Merck KGaA announced the establishment of an upstream technology research and development (R&D) center in Shanghai.
China-based Sino Biopharmaceutical Ltd (01177.HK) announced that its marketing filing for pomalidomide capsules, a derivative of the Celgene-marketed multiple myeloma therapy thalidomide, has been accepted by the China National Drug Administration (CNDA)’s Center for Drug Evaluation (CDE).
  • 1534476319668
  • China
  • Drug
China-based Sino Biopharmaceutical Limited (1177.HK) announced the initiation of Phase I clinical trials for the firm's pertuzumab injection, a therapeutic biologic for the treatment of breast cancer.
  • 1533804165497
  • China
  • Drug
China-based Sino Biopharmaceutical Ltd (HK.01177) announced that the anti-cancer drug docetaxel injection, developed by the firm's subsidiary Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd, (CTTQ) received marketing approval from the China National Drug Administration (CNDA).
  • 1530154866561
  • China
  • Drug
Recent news
编者按:本文转载自同写意,作者孟八一。
  • 1550364318605
  • China
作者:药疯 由于患病人口数量庞大、后续并发致残致死率高、经济负担重、疾病重视程度低等特点,一直以来,心脑血管疾病都是严重威胁人类生命健康的重要疾病。
  • 1550364307286
  • China
日前,美国FierceBiotech网站公布了年度15家医疗技术“猛”公司(Fierce 15)的榜单。
  • 1550364307125
  • China
近日,美国食品药品监督管理局(FDA)小组联合投票批准艾氯胺酮鼻腔喷雾剂(28mg/次)可用于难治性抑郁症(TRD)的治疗。
  • 1550364305337
  • China
2019年2月16日 讯 /生物谷BIOON/ --最近,来自ITMO的科学家与国际同事合作,提出了新的靶向DNA的纳米机器,可用于癌症的基因治疗。
  • 1550364298943
  • China
2019年2月16日 讯 /生物谷BIOON/ --神奇材料石墨烯可以成为解锁下一代早期肺癌诊断的关键。
  • 1550364298851
  • China
2019年2月16日 讯 /生物谷BIOON/ --美国能源部橡树岭国家实验室的科学家在《Science》杂志上首次描述了使用电子显微镜直接识别纳米级氨基酸中的同位素而不损坏样品的结果。
  • 1550364298761
  • China
Analytics Snapshot


Understand market developments and maintain your competitive advantage.